nodes	percent_of_prediction	percent_of_DWPC	metapath
Cefotetan—ALB—Abiraterone—prostate cancer	0.279	0.401	CbGbCtD
Cefotetan—ALB—Estrone—prostate cancer	0.201	0.29	CbGbCtD
Cefotetan—ALB—Estradiol—prostate cancer	0.116	0.166	CbGbCtD
Cefotetan—ALB—Prednisone—prostate cancer	0.0995	0.143	CbGbCtD
Cefotetan—Cefazolin—PON1—prostate cancer	0.00141	1	CrCbGaD
Cefotetan—Neutropenia—Mitoxantrone—prostate cancer	0.000643	0.00238	CcSEcCtD
Cefotetan—Phlebitis—Docetaxel—prostate cancer	0.000638	0.00236	CcSEcCtD
Cefotetan—Vomiting—Estradiol valerate/Dienogest—prostate cancer	0.00063	0.00233	CcSEcCtD
Cefotetan—Nausea—Nilutamide—prostate cancer	0.000626	0.00231	CcSEcCtD
Cefotetan—Rash—Estradiol valerate/Dienogest—prostate cancer	0.000624	0.00231	CcSEcCtD
Cefotetan—Dermatitis—Estradiol valerate/Dienogest—prostate cancer	0.000624	0.00231	CcSEcCtD
Cefotetan—Nausea—Flutamide—prostate cancer	0.000623	0.0023	CcSEcCtD
Cefotetan—Gastrointestinal pain—Bicalutamide—prostate cancer	0.000622	0.0023	CcSEcCtD
Cefotetan—Phlebitis—Capecitabine—prostate cancer	0.000618	0.00228	CcSEcCtD
Cefotetan—Hepatic function abnormal—Capecitabine—prostate cancer	0.000609	0.00225	CcSEcCtD
Cefotetan—Diarrhoea—Cabazitaxel—prostate cancer	0.000607	0.00224	CcSEcCtD
Cefotetan—Urticaria—Bicalutamide—prostate cancer	0.000604	0.00223	CcSEcCtD
Cefotetan—Body temperature increased—Bicalutamide—prostate cancer	0.000602	0.00222	CcSEcCtD
Cefotetan—Abdominal pain—Bicalutamide—prostate cancer	0.000602	0.00222	CcSEcCtD
Cefotetan—Vomiting—Degarelix—prostate cancer	0.000599	0.00221	CcSEcCtD
Cefotetan—Toxic epidermal necrolysis—Etoposide—prostate cancer	0.000596	0.0022	CcSEcCtD
Cefotetan—Rash—Degarelix—prostate cancer	0.000594	0.00219	CcSEcCtD
Cefotetan—Haemoglobin—Estradiol—prostate cancer	0.000594	0.00219	CcSEcCtD
Cefotetan—Dermatitis—Degarelix—prostate cancer	0.000593	0.00219	CcSEcCtD
Cefotetan—Haemorrhage—Estradiol—prostate cancer	0.000591	0.00218	CcSEcCtD
Cefotetan—Haemolytic anaemia—Capecitabine—prostate cancer	0.00059	0.00218	CcSEcCtD
Cefotetan—Nausea—Estradiol valerate/Dienogest—prostate cancer	0.000588	0.00217	CcSEcCtD
Cefotetan—Leukopenia—Goserelin—prostate cancer	0.000581	0.00215	CcSEcCtD
Cefotetan—Agranulocytosis—Mitoxantrone—prostate cancer	0.000572	0.00211	CcSEcCtD
Cefotetan—Vomiting—Cabazitaxel—prostate cancer	0.000564	0.00208	CcSEcCtD
Cefotetan—Convulsion—Goserelin—prostate cancer	0.000562	0.00208	CcSEcCtD
Cefotetan—Hypersensitivity—Bicalutamide—prostate cancer	0.000561	0.00207	CcSEcCtD
Cefotetan—Nausea—Degarelix—prostate cancer	0.000559	0.00207	CcSEcCtD
Cefotetan—Erythema multiforme—Estradiol—prostate cancer	0.000558	0.00206	CcSEcCtD
Cefotetan—Convulsion—Conjugated Estrogens—prostate cancer	0.000557	0.00206	CcSEcCtD
Cefotetan—Haemoglobin—Mitoxantrone—prostate cancer	0.000553	0.00204	CcSEcCtD
Cefotetan—Haemorrhage—Mitoxantrone—prostate cancer	0.00055	0.00203	CcSEcCtD
Cefotetan—Discomfort—Goserelin—prostate cancer	0.000546	0.00202	CcSEcCtD
Cefotetan—Pancytopenia—Etoposide—prostate cancer	0.000543	0.00201	CcSEcCtD
Cefotetan—Blood bilirubin increased—Epirubicin—prostate cancer	0.00054	0.002	CcSEcCtD
Cefotetan—Pruritus—Bicalutamide—prostate cancer	0.000538	0.00199	CcSEcCtD
Cefotetan—Neutropenia—Etoposide—prostate cancer	0.000535	0.00198	CcSEcCtD
Cefotetan—Anaphylactic shock—Goserelin—prostate cancer	0.000529	0.00196	CcSEcCtD
Cefotetan—Nausea—Cabazitaxel—prostate cancer	0.000527	0.00195	CcSEcCtD
Cefotetan—Gastrointestinal pain—Ethinyl Estradiol—prostate cancer	0.000526	0.00194	CcSEcCtD
Cefotetan—Anaphylactic shock—Conjugated Estrogens—prostate cancer	0.000524	0.00194	CcSEcCtD
Cefotetan—Diarrhoea—Bicalutamide—prostate cancer	0.000521	0.00192	CcSEcCtD
Cefotetan—Thrombocytopenia—Goserelin—prostate cancer	0.000518	0.00192	CcSEcCtD
Cefotetan—Vaginal inflammation—Epirubicin—prostate cancer	0.000511	0.00189	CcSEcCtD
Cefotetan—Urticaria—Ethinyl Estradiol—prostate cancer	0.000511	0.00189	CcSEcCtD
Cefotetan—Abdominal pain—Ethinyl Estradiol—prostate cancer	0.000508	0.00188	CcSEcCtD
Cefotetan—Body temperature increased—Ethinyl Estradiol—prostate cancer	0.000508	0.00188	CcSEcCtD
Cefotetan—Stevens-Johnson syndrome—Etoposide—prostate cancer	0.000506	0.00187	CcSEcCtD
Cefotetan—Blood bilirubin increased—Doxorubicin—prostate cancer	0.0005	0.00185	CcSEcCtD
Cefotetan—Toxic epidermal necrolysis—Docetaxel—prostate cancer	0.000495	0.00183	CcSEcCtD
Cefotetan—Colitis—Epirubicin—prostate cancer	0.000491	0.00181	CcSEcCtD
Cefotetan—Vomiting—Bicalutamide—prostate cancer	0.000484	0.00179	CcSEcCtD
Cefotetan—Vaginal infection—Epirubicin—prostate cancer	0.000482	0.00178	CcSEcCtD
Cefotetan—Rash—Bicalutamide—prostate cancer	0.00048	0.00177	CcSEcCtD
Cefotetan—Aplastic anaemia—Epirubicin—prostate cancer	0.00048	0.00177	CcSEcCtD
Cefotetan—Toxic epidermal necrolysis—Capecitabine—prostate cancer	0.000479	0.00177	CcSEcCtD
Cefotetan—Dermatitis—Bicalutamide—prostate cancer	0.000479	0.00177	CcSEcCtD
Cefotetan—Agranulocytosis—Etoposide—prostate cancer	0.000476	0.00176	CcSEcCtD
Cefotetan—Hypersensitivity—Ethinyl Estradiol—prostate cancer	0.000474	0.00175	CcSEcCtD
Cefotetan—Vaginal inflammation—Doxorubicin—prostate cancer	0.000473	0.00175	CcSEcCtD
Cefotetan—Pruritus—Ethinyl Estradiol—prostate cancer	0.000455	0.00168	CcSEcCtD
Cefotetan—Colitis—Doxorubicin—prostate cancer	0.000454	0.00168	CcSEcCtD
Cefotetan—Nausea—Bicalutamide—prostate cancer	0.000452	0.00167	CcSEcCtD
Cefotetan—Pancytopenia—Docetaxel—prostate cancer	0.000451	0.00167	CcSEcCtD
Cefotetan—Vaginal infection—Doxorubicin—prostate cancer	0.000446	0.00165	CcSEcCtD
Cefotetan—Neutropenia—Docetaxel—prostate cancer	0.000444	0.00164	CcSEcCtD
Cefotetan—Aplastic anaemia—Doxorubicin—prostate cancer	0.000444	0.00164	CcSEcCtD
Cefotetan—Diarrhoea—Ethinyl Estradiol—prostate cancer	0.00044	0.00163	CcSEcCtD
Cefotetan—Pancytopenia—Capecitabine—prostate cancer	0.000437	0.00162	CcSEcCtD
Cefotetan—Gastrointestinal pain—Goserelin—prostate cancer	0.000433	0.0016	CcSEcCtD
Cefotetan—Erythema multiforme—Etoposide—prostate cancer	0.000433	0.0016	CcSEcCtD
Cefotetan—Discomfort—Estradiol—prostate cancer	0.000432	0.0016	CcSEcCtD
Cefotetan—Phlebitis—Epirubicin—prostate cancer	0.000431	0.00159	CcSEcCtD
Cefotetan—Neutropenia—Capecitabine—prostate cancer	0.00043	0.00159	CcSEcCtD
Cefotetan—Leukopenia—Mitoxantrone—prostate cancer	0.000429	0.00159	CcSEcCtD
Cefotetan—Gastrointestinal pain—Conjugated Estrogens—prostate cancer	0.000429	0.00158	CcSEcCtD
Cefotetan—Hepatic function abnormal—Epirubicin—prostate cancer	0.000424	0.00157	CcSEcCtD
Cefotetan—Urticaria—Goserelin—prostate cancer	0.000421	0.00155	CcSEcCtD
Cefotetan—Stevens-Johnson syndrome—Docetaxel—prostate cancer	0.00042	0.00155	CcSEcCtD
Cefotetan—Anaphylactic shock—Estradiol—prostate cancer	0.00042	0.00155	CcSEcCtD
Cefotetan—Abdominal pain—Goserelin—prostate cancer	0.000418	0.00155	CcSEcCtD
Cefotetan—Body temperature increased—Goserelin—prostate cancer	0.000418	0.00155	CcSEcCtD
Cefotetan—Urticaria—Conjugated Estrogens—prostate cancer	0.000417	0.00154	CcSEcCtD
Cefotetan—Convulsion—Mitoxantrone—prostate cancer	0.000415	0.00153	CcSEcCtD
Cefotetan—Abdominal pain—Conjugated Estrogens—prostate cancer	0.000414	0.00153	CcSEcCtD
Cefotetan—Body temperature increased—Conjugated Estrogens—prostate cancer	0.000414	0.00153	CcSEcCtD
Cefotetan—Vomiting—Ethinyl Estradiol—prostate cancer	0.000409	0.00151	CcSEcCtD
Cefotetan—Stevens-Johnson syndrome—Capecitabine—prostate cancer	0.000407	0.0015	CcSEcCtD
Cefotetan—Rash—Ethinyl Estradiol—prostate cancer	0.000406	0.0015	CcSEcCtD
Cefotetan—Dermatitis—Ethinyl Estradiol—prostate cancer	0.000405	0.0015	CcSEcCtD
Cefotetan—Discomfort—Mitoxantrone—prostate cancer	0.000403	0.00149	CcSEcCtD
Cefotetan—Phlebitis—Doxorubicin—prostate cancer	0.000398	0.00147	CcSEcCtD
Cefotetan—Agranulocytosis—Docetaxel—prostate cancer	0.000395	0.00146	CcSEcCtD
Cefotetan—Hepatic function abnormal—Doxorubicin—prostate cancer	0.000393	0.00145	CcSEcCtD
Cefotetan—Anaphylactic shock—Mitoxantrone—prostate cancer	0.000391	0.00145	CcSEcCtD
Cefotetan—Hypersensitivity—Goserelin—prostate cancer	0.00039	0.00144	CcSEcCtD
Cefotetan—Hypersensitivity—Conjugated Estrogens—prostate cancer	0.000386	0.00143	CcSEcCtD
Cefotetan—Neutropenia—Prednisone—prostate cancer	0.000383	0.00142	CcSEcCtD
Cefotetan—Agranulocytosis—Capecitabine—prostate cancer	0.000383	0.00142	CcSEcCtD
Cefotetan—Thrombocytopenia—Mitoxantrone—prostate cancer	0.000383	0.00142	CcSEcCtD
Cefotetan—Haemoglobin—Docetaxel—prostate cancer	0.000382	0.00141	CcSEcCtD
Cefotetan—Nausea—Ethinyl Estradiol—prostate cancer	0.000382	0.00141	CcSEcCtD
Cefotetan—Haemorrhage—Docetaxel—prostate cancer	0.00038	0.00141	CcSEcCtD
Cefotetan—Pruritus—Goserelin—prostate cancer	0.000375	0.00138	CcSEcCtD
Cefotetan—Pruritus—Conjugated Estrogens—prostate cancer	0.000371	0.00137	CcSEcCtD
Cefotetan—Haemoglobin—Capecitabine—prostate cancer	0.00037	0.00137	CcSEcCtD
Cefotetan—Haemorrhage—Capecitabine—prostate cancer	0.000368	0.00136	CcSEcCtD
Cefotetan—Diarrhoea—Goserelin—prostate cancer	0.000362	0.00134	CcSEcCtD
Cefotetan—Erythema multiforme—Docetaxel—prostate cancer	0.00036	0.00133	CcSEcCtD
Cefotetan—Diarrhoea—Conjugated Estrogens—prostate cancer	0.000359	0.00133	CcSEcCtD
Cefotetan—Leukopenia—Etoposide—prostate cancer	0.000357	0.00132	CcSEcCtD
Cefotetan—Erythema multiforme—Capecitabine—prostate cancer	0.000348	0.00129	CcSEcCtD
Cefotetan—Convulsion—Etoposide—prostate cancer	0.000345	0.00128	CcSEcCtD
Cefotetan—Gastrointestinal pain—Estradiol—prostate cancer	0.000343	0.00127	CcSEcCtD
Cefotetan—Vomiting—Goserelin—prostate cancer	0.000337	0.00124	CcSEcCtD
Cefotetan—Discomfort—Etoposide—prostate cancer	0.000335	0.00124	CcSEcCtD
Cefotetan—Toxic epidermal necrolysis—Epirubicin—prostate cancer	0.000334	0.00123	CcSEcCtD
Cefotetan—Rash—Goserelin—prostate cancer	0.000334	0.00123	CcSEcCtD
Cefotetan—Dermatitis—Goserelin—prostate cancer	0.000333	0.00123	CcSEcCtD
Cefotetan—Vomiting—Conjugated Estrogens—prostate cancer	0.000333	0.00123	CcSEcCtD
Cefotetan—Urticaria—Estradiol—prostate cancer	0.000333	0.00123	CcSEcCtD
Cefotetan—Abdominal pain—Estradiol—prostate cancer	0.000332	0.00123	CcSEcCtD
Cefotetan—Body temperature increased—Estradiol—prostate cancer	0.000332	0.00123	CcSEcCtD
Cefotetan—Rash—Conjugated Estrogens—prostate cancer	0.000331	0.00122	CcSEcCtD
Cefotetan—Dermatitis—Conjugated Estrogens—prostate cancer	0.00033	0.00122	CcSEcCtD
Cefotetan—Haemoglobin—Prednisone—prostate cancer	0.00033	0.00122	CcSEcCtD
Cefotetan—Haemorrhage—Prednisone—prostate cancer	0.000328	0.00121	CcSEcCtD
Cefotetan—Anaphylactic shock—Etoposide—prostate cancer	0.000325	0.0012	CcSEcCtD
Cefotetan—Gastrointestinal pain—Mitoxantrone—prostate cancer	0.00032	0.00118	CcSEcCtD
Cefotetan—Thrombocytopenia—Etoposide—prostate cancer	0.000318	0.00118	CcSEcCtD
Cefotetan—Eosinophilia—Epirubicin—prostate cancer	0.000317	0.00117	CcSEcCtD
Cefotetan—Nausea—Goserelin—prostate cancer	0.000314	0.00116	CcSEcCtD
Cefotetan—Nausea—Conjugated Estrogens—prostate cancer	0.000311	0.00115	CcSEcCtD
Cefotetan—Urticaria—Mitoxantrone—prostate cancer	0.000311	0.00115	CcSEcCtD
Cefotetan—Hypersensitivity—Estradiol—prostate cancer	0.000309	0.00114	CcSEcCtD
Cefotetan—Abdominal pain—Mitoxantrone—prostate cancer	0.000309	0.00114	CcSEcCtD
Cefotetan—Body temperature increased—Mitoxantrone—prostate cancer	0.000309	0.00114	CcSEcCtD
Cefotetan—Toxic epidermal necrolysis—Doxorubicin—prostate cancer	0.000309	0.00114	CcSEcCtD
Cefotetan—Pancytopenia—Epirubicin—prostate cancer	0.000304	0.00113	CcSEcCtD
Cefotetan—Neutropenia—Epirubicin—prostate cancer	0.0003	0.00111	CcSEcCtD
Cefotetan—Pruritus—Estradiol—prostate cancer	0.000297	0.0011	CcSEcCtD
Cefotetan—Leukopenia—Docetaxel—prostate cancer	0.000296	0.0011	CcSEcCtD
Cefotetan—Eosinophilia—Doxorubicin—prostate cancer	0.000294	0.00109	CcSEcCtD
Cefotetan—Hypersensitivity—Mitoxantrone—prostate cancer	0.000288	0.00106	CcSEcCtD
Cefotetan—Diarrhoea—Estradiol—prostate cancer	0.000287	0.00106	CcSEcCtD
Cefotetan—Leukopenia—Capecitabine—prostate cancer	0.000287	0.00106	CcSEcCtD
Cefotetan—Convulsion—Docetaxel—prostate cancer	0.000287	0.00106	CcSEcCtD
Cefotetan—Stevens-Johnson syndrome—Epirubicin—prostate cancer	0.000283	0.00105	CcSEcCtD
Cefotetan—Pancytopenia—Doxorubicin—prostate cancer	0.000282	0.00104	CcSEcCtD
Cefotetan—Neutropenia—Doxorubicin—prostate cancer	0.000277	0.00103	CcSEcCtD
Cefotetan—Anaphylactic shock—Docetaxel—prostate cancer	0.00027	0.000999	CcSEcCtD
Cefotetan—Discomfort—Capecitabine—prostate cancer	0.00027	0.000997	CcSEcCtD
Cefotetan—Diarrhoea—Mitoxantrone—prostate cancer	0.000268	0.000989	CcSEcCtD
Cefotetan—Vomiting—Estradiol—prostate cancer	0.000267	0.000986	CcSEcCtD
Cefotetan—Agranulocytosis—Epirubicin—prostate cancer	0.000267	0.000986	CcSEcCtD
Cefotetan—Gastrointestinal pain—Etoposide—prostate cancer	0.000266	0.000983	CcSEcCtD
Cefotetan—Thrombocytopenia—Docetaxel—prostate cancer	0.000265	0.000978	CcSEcCtD
Cefotetan—Rash—Estradiol—prostate cancer	0.000265	0.000978	CcSEcCtD
Cefotetan—Dermatitis—Estradiol—prostate cancer	0.000264	0.000977	CcSEcCtD
Cefotetan—Stevens-Johnson syndrome—Doxorubicin—prostate cancer	0.000262	0.000969	CcSEcCtD
Cefotetan—Urticaria—Etoposide—prostate cancer	0.000258	0.000955	CcSEcCtD
Cefotetan—Haemoglobin—Epirubicin—prostate cancer	0.000258	0.000953	CcSEcCtD
Cefotetan—Abdominal pain—Etoposide—prostate cancer	0.000257	0.00095	CcSEcCtD
Cefotetan—Body temperature increased—Etoposide—prostate cancer	0.000257	0.00095	CcSEcCtD
Cefotetan—Haemorrhage—Epirubicin—prostate cancer	0.000257	0.000948	CcSEcCtD
Cefotetan—Thrombocytopenia—Capecitabine—prostate cancer	0.000256	0.000947	CcSEcCtD
Cefotetan—Nausea—Estradiol—prostate cancer	0.000249	0.000921	CcSEcCtD
Cefotetan—Vomiting—Mitoxantrone—prostate cancer	0.000249	0.000919	CcSEcCtD
Cefotetan—Convulsion—Prednisone—prostate cancer	0.000247	0.000915	CcSEcCtD
Cefotetan—Agranulocytosis—Doxorubicin—prostate cancer	0.000247	0.000912	CcSEcCtD
Cefotetan—Rash—Mitoxantrone—prostate cancer	0.000247	0.000911	CcSEcCtD
Cefotetan—Dermatitis—Mitoxantrone—prostate cancer	0.000246	0.00091	CcSEcCtD
Cefotetan—Erythema multiforme—Epirubicin—prostate cancer	0.000243	0.000897	CcSEcCtD
Cefotetan—Discomfort—Prednisone—prostate cancer	0.00024	0.000888	CcSEcCtD
Cefotetan—Hypersensitivity—Etoposide—prostate cancer	0.00024	0.000886	CcSEcCtD
Cefotetan—Haemoglobin—Doxorubicin—prostate cancer	0.000239	0.000882	CcSEcCtD
Cefotetan—Haemorrhage—Doxorubicin—prostate cancer	0.000237	0.000878	CcSEcCtD
Cefotetan—Anaphylactic shock—Prednisone—prostate cancer	0.000233	0.000862	CcSEcCtD
Cefotetan—Nausea—Mitoxantrone—prostate cancer	0.000232	0.000858	CcSEcCtD
Cefotetan—Pruritus—Etoposide—prostate cancer	0.00023	0.000851	CcSEcCtD
Cefotetan—Erythema multiforme—Doxorubicin—prostate cancer	0.000224	0.00083	CcSEcCtD
Cefotetan—Diarrhoea—Etoposide—prostate cancer	0.000223	0.000823	CcSEcCtD
Cefotetan—Gastrointestinal pain—Docetaxel—prostate cancer	0.000221	0.000817	CcSEcCtD
Cefotetan—Gastrointestinal pain—Capecitabine—prostate cancer	0.000214	0.000791	CcSEcCtD
Cefotetan—Abdominal pain—Docetaxel—prostate cancer	0.000214	0.00079	CcSEcCtD
Cefotetan—Body temperature increased—Docetaxel—prostate cancer	0.000214	0.00079	CcSEcCtD
Cefotetan—Urticaria—Capecitabine—prostate cancer	0.000208	0.000768	CcSEcCtD
Cefotetan—Body temperature increased—Capecitabine—prostate cancer	0.000207	0.000765	CcSEcCtD
Cefotetan—Abdominal pain—Capecitabine—prostate cancer	0.000207	0.000765	CcSEcCtD
Cefotetan—Vomiting—Etoposide—prostate cancer	0.000207	0.000764	CcSEcCtD
Cefotetan—Rash—Etoposide—prostate cancer	0.000205	0.000758	CcSEcCtD
Cefotetan—Dermatitis—Etoposide—prostate cancer	0.000205	0.000757	CcSEcCtD
Cefotetan—Leukopenia—Epirubicin—prostate cancer	0.0002	0.000739	CcSEcCtD
Cefotetan—Hypersensitivity—Docetaxel—prostate cancer	0.000199	0.000736	CcSEcCtD
Cefotetan—Convulsion—Epirubicin—prostate cancer	0.000194	0.000715	CcSEcCtD
Cefotetan—Nausea—Etoposide—prostate cancer	0.000193	0.000714	CcSEcCtD
Cefotetan—Hypersensitivity—Capecitabine—prostate cancer	0.000193	0.000713	CcSEcCtD
Cefotetan—Pruritus—Docetaxel—prostate cancer	0.000191	0.000707	CcSEcCtD
Cefotetan—Gastrointestinal pain—Prednisone—prostate cancer	0.000191	0.000705	CcSEcCtD
Cefotetan—Discomfort—Epirubicin—prostate cancer	0.000188	0.000695	CcSEcCtD
Cefotetan—Urticaria—Prednisone—prostate cancer	0.000185	0.000684	CcSEcCtD
Cefotetan—Pruritus—Capecitabine—prostate cancer	0.000185	0.000684	CcSEcCtD
Cefotetan—Leukopenia—Doxorubicin—prostate cancer	0.000185	0.000684	CcSEcCtD
Cefotetan—Diarrhoea—Docetaxel—prostate cancer	0.000185	0.000684	CcSEcCtD
Cefotetan—Body temperature increased—Prednisone—prostate cancer	0.000184	0.000681	CcSEcCtD
Cefotetan—Abdominal pain—Prednisone—prostate cancer	0.000184	0.000681	CcSEcCtD
Cefotetan—Anaphylactic shock—Epirubicin—prostate cancer	0.000182	0.000674	CcSEcCtD
Cefotetan—Convulsion—Doxorubicin—prostate cancer	0.000179	0.000662	CcSEcCtD
Cefotetan—Diarrhoea—Capecitabine—prostate cancer	0.000179	0.000662	CcSEcCtD
Cefotetan—Thrombocytopenia—Epirubicin—prostate cancer	0.000178	0.00066	CcSEcCtD
Cefotetan—Discomfort—Doxorubicin—prostate cancer	0.000174	0.000643	CcSEcCtD
Cefotetan—Vomiting—Docetaxel—prostate cancer	0.000172	0.000635	CcSEcCtD
Cefotetan—Hypersensitivity—Prednisone—prostate cancer	0.000172	0.000635	CcSEcCtD
Cefotetan—Rash—Docetaxel—prostate cancer	0.00017	0.00063	CcSEcCtD
Cefotetan—Dermatitis—Docetaxel—prostate cancer	0.00017	0.000629	CcSEcCtD
Cefotetan—Anaphylactic shock—Doxorubicin—prostate cancer	0.000169	0.000624	CcSEcCtD
Cefotetan—Vomiting—Capecitabine—prostate cancer	0.000166	0.000615	CcSEcCtD
Cefotetan—Thrombocytopenia—Doxorubicin—prostate cancer	0.000165	0.00061	CcSEcCtD
Cefotetan—Rash—Capecitabine—prostate cancer	0.000165	0.00061	CcSEcCtD
Cefotetan—Pruritus—Prednisone—prostate cancer	0.000165	0.00061	CcSEcCtD
Cefotetan—Dermatitis—Capecitabine—prostate cancer	0.000165	0.000609	CcSEcCtD
Cefotetan—Nausea—Docetaxel—prostate cancer	0.000161	0.000593	CcSEcCtD
Cefotetan—Diarrhoea—Prednisone—prostate cancer	0.000159	0.00059	CcSEcCtD
Cefotetan—Nausea—Capecitabine—prostate cancer	0.000155	0.000575	CcSEcCtD
Cefotetan—Gastrointestinal pain—Epirubicin—prostate cancer	0.000149	0.000551	CcSEcCtD
Cefotetan—Vomiting—Prednisone—prostate cancer	0.000148	0.000548	CcSEcCtD
Cefotetan—Rash—Prednisone—prostate cancer	0.000147	0.000543	CcSEcCtD
Cefotetan—Dermatitis—Prednisone—prostate cancer	0.000147	0.000543	CcSEcCtD
Cefotetan—Urticaria—Epirubicin—prostate cancer	0.000145	0.000535	CcSEcCtD
Cefotetan—Abdominal pain—Epirubicin—prostate cancer	0.000144	0.000533	CcSEcCtD
Cefotetan—Body temperature increased—Epirubicin—prostate cancer	0.000144	0.000533	CcSEcCtD
Cefotetan—Nausea—Prednisone—prostate cancer	0.000138	0.000512	CcSEcCtD
Cefotetan—Gastrointestinal pain—Doxorubicin—prostate cancer	0.000138	0.00051	CcSEcCtD
Cefotetan—Hypersensitivity—Epirubicin—prostate cancer	0.000134	0.000496	CcSEcCtD
Cefotetan—Urticaria—Doxorubicin—prostate cancer	0.000134	0.000495	CcSEcCtD
Cefotetan—Body temperature increased—Doxorubicin—prostate cancer	0.000133	0.000493	CcSEcCtD
Cefotetan—Abdominal pain—Doxorubicin—prostate cancer	0.000133	0.000493	CcSEcCtD
Cefotetan—Pruritus—Epirubicin—prostate cancer	0.000129	0.000477	CcSEcCtD
Cefotetan—Diarrhoea—Epirubicin—prostate cancer	0.000125	0.000461	CcSEcCtD
Cefotetan—Hypersensitivity—Doxorubicin—prostate cancer	0.000124	0.000459	CcSEcCtD
Cefotetan—Pruritus—Doxorubicin—prostate cancer	0.000119	0.000441	CcSEcCtD
Cefotetan—ALB—Metabolism of lipids and lipoproteins—GRHL1—prostate cancer	0.000116	0.00356	CbGpPWpGaD
Cefotetan—ALB—Vitamin B12 Metabolism—SERPINE1—prostate cancer	0.000116	0.00355	CbGpPWpGaD
Cefotetan—Vomiting—Epirubicin—prostate cancer	0.000116	0.000428	CcSEcCtD
Cefotetan—Diarrhoea—Doxorubicin—prostate cancer	0.000115	0.000427	CcSEcCtD
Cefotetan—Rash—Epirubicin—prostate cancer	0.000115	0.000425	CcSEcCtD
Cefotetan—Dermatitis—Epirubicin—prostate cancer	0.000115	0.000424	CcSEcCtD
Cefotetan—ALB—Response to elevated platelet cytosolic Ca2+—ITGB3—prostate cancer	0.000113	0.00346	CbGpPWpGaD
Cefotetan—ALB—Folate Metabolism—ICAM1—prostate cancer	0.000113	0.00346	CbGpPWpGaD
Cefotetan—ALB—Platelet activation, signaling and aggregation—CLU—prostate cancer	0.000113	0.00344	CbGpPWpGaD
Cefotetan—ALB—SLC-mediated transmembrane transport—SLC22A3—prostate cancer	0.000111	0.00339	CbGpPWpGaD
Cefotetan—ALB—Transmembrane transport of small molecules—SLC7A1—prostate cancer	0.000111	0.00338	CbGpPWpGaD
Cefotetan—Nausea—Epirubicin—prostate cancer	0.000108	0.0004	CcSEcCtD
Cefotetan—Vomiting—Doxorubicin—prostate cancer	0.000107	0.000396	CcSEcCtD
Cefotetan—Rash—Doxorubicin—prostate cancer	0.000106	0.000393	CcSEcCtD
Cefotetan—Dermatitis—Doxorubicin—prostate cancer	0.000106	0.000393	CcSEcCtD
Cefotetan—ALB—Folate Metabolism—INS—prostate cancer	0.000103	0.00314	CbGpPWpGaD
Cefotetan—ALB—Selenium Micronutrient Network—MTHFR—prostate cancer	0.000103	0.00314	CbGpPWpGaD
Cefotetan—ALB—Metabolism of lipids and lipoproteins—MBTPS1—prostate cancer	0.000102	0.00311	CbGpPWpGaD
Cefotetan—Nausea—Doxorubicin—prostate cancer	0.0001	0.00037	CcSEcCtD
Cefotetan—ALB—Platelet activation, signaling and aggregation—GNG5—prostate cancer	9.79e-05	0.003	CbGpPWpGaD
Cefotetan—ALB—Hemostasis—STX4—prostate cancer	9.68e-05	0.00296	CbGpPWpGaD
Cefotetan—ALB—Hemostasis—RAD51B—prostate cancer	9.68e-05	0.00296	CbGpPWpGaD
Cefotetan—ALB—Metabolism of lipids and lipoproteins—AMACR—prostate cancer	9.64e-05	0.00295	CbGpPWpGaD
Cefotetan—ALB—Metabolism of lipids and lipoproteins—SRD5A2—prostate cancer	9.64e-05	0.00295	CbGpPWpGaD
Cefotetan—ALB—Metabolism of lipids and lipoproteins—DEGS1—prostate cancer	9.64e-05	0.00295	CbGpPWpGaD
Cefotetan—ALB—Folate Metabolism—SERPINE1—prostate cancer	9.43e-05	0.00289	CbGpPWpGaD
Cefotetan—ALB—Platelet degranulation—EGF—prostate cancer	9.19e-05	0.00281	CbGpPWpGaD
Cefotetan—ALB—Metabolism of lipids and lipoproteins—HSD17B1—prostate cancer	9.19e-05	0.00281	CbGpPWpGaD
Cefotetan—ALB—SLC-mediated transmembrane transport—SLC22A1—prostate cancer	9.04e-05	0.00277	CbGpPWpGaD
Cefotetan—ALB—Selenium Micronutrient Network—ICAM1—prostate cancer	8.97e-05	0.00275	CbGpPWpGaD
Cefotetan—ALB—Response to elevated platelet cytosolic Ca2+—EGF—prostate cancer	8.76e-05	0.00268	CbGpPWpGaD
Cefotetan—ALB—Transmembrane transport of small molecules—SLC39A1—prostate cancer	8.74e-05	0.00268	CbGpPWpGaD
Cefotetan—ALB—Hemostasis—F9—prostate cancer	8.72e-05	0.00267	CbGpPWpGaD
Cefotetan—ALB—Platelet degranulation—IGF1—prostate cancer	8.52e-05	0.00261	CbGpPWpGaD
Cefotetan—ALB—Metabolism of lipids and lipoproteins—HPGD—prostate cancer	8.19e-05	0.00251	CbGpPWpGaD
Cefotetan—ALB—Selenium Micronutrient Network—INS—prostate cancer	8.16e-05	0.0025	CbGpPWpGaD
Cefotetan—ALB—Platelet activation, signaling and aggregation—THBS1—prostate cancer	8.13e-05	0.00249	CbGpPWpGaD
Cefotetan—ALB—Response to elevated platelet cytosolic Ca2+—IGF1—prostate cancer	8.11e-05	0.00248	CbGpPWpGaD
Cefotetan—ALB—Platelet degranulation—SERPINE1—prostate cancer	8.09e-05	0.00248	CbGpPWpGaD
Cefotetan—ALB—Platelet activation, signaling and aggregation—PRKCZ—prostate cancer	7.87e-05	0.00241	CbGpPWpGaD
Cefotetan—ALB—Response to elevated platelet cytosolic Ca2+—SERPINE1—prostate cancer	7.71e-05	0.00236	CbGpPWpGaD
Cefotetan—ALB—Metabolism of lipids and lipoproteins—TNFRSF21—prostate cancer	7.7e-05	0.00236	CbGpPWpGaD
Cefotetan—ALB—Folate Metabolism—IL2—prostate cancer	7.63e-05	0.00234	CbGpPWpGaD
Cefotetan—ALB—Selenium Micronutrient Network—SERPINE1—prostate cancer	7.49e-05	0.00229	CbGpPWpGaD
Cefotetan—ALB—Metabolism of lipids and lipoproteins—CYP7B1—prostate cancer	7.49e-05	0.00229	CbGpPWpGaD
Cefotetan—ALB—Metabolism of lipids and lipoproteins—SRD5A1—prostate cancer	7.3e-05	0.00224	CbGpPWpGaD
Cefotetan—ALB—Transmembrane transport of small molecules—CYP7B1—prostate cancer	7.13e-05	0.00218	CbGpPWpGaD
Cefotetan—ALB—Metabolism of lipids and lipoproteins—ACSL4—prostate cancer	6.97e-05	0.00213	CbGpPWpGaD
Cefotetan—ALB—Metabolism of lipids and lipoproteins—HSD17B3—prostate cancer	6.97e-05	0.00213	CbGpPWpGaD
Cefotetan—ALB—Transmembrane transport of small molecules—SLC12A2—prostate cancer	6.94e-05	0.00213	CbGpPWpGaD
Cefotetan—ALB—Transmembrane transport of small molecules—SLC26A4—prostate cancer	6.94e-05	0.00213	CbGpPWpGaD
Cefotetan—ALB—Hemostasis—ITGA6—prostate cancer	6.82e-05	0.00209	CbGpPWpGaD
Cefotetan—ALB—Platelet activation, signaling and aggregation—PRKCQ—prostate cancer	6.69e-05	0.00205	CbGpPWpGaD
Cefotetan—ALB—SLC-mediated transmembrane transport—SLC5A5—prostate cancer	6.59e-05	0.00202	CbGpPWpGaD
Cefotetan—ALB—Selenium Micronutrient Network—PTGS2—prostate cancer	6.54e-05	0.002	CbGpPWpGaD
Cefotetan—ALB—Hemostasis—CD9—prostate cancer	6.41e-05	0.00196	CbGpPWpGaD
Cefotetan—ALB—Metabolism—HAO1—prostate cancer	6.35e-05	0.00194	CbGpPWpGaD
Cefotetan—ALB—Platelet activation, signaling and aggregation—VAV3—prostate cancer	6.13e-05	0.00188	CbGpPWpGaD
Cefotetan—ALB—Platelet activation, signaling and aggregation—ITPR1—prostate cancer	5.95e-05	0.00182	CbGpPWpGaD
Cefotetan—ALB—Metabolism of lipids and lipoproteins—HSD3B1—prostate cancer	5.92e-05	0.00181	CbGpPWpGaD
Cefotetan—ALB—Hemostasis—CLU—prostate cancer	5.8e-05	0.00178	CbGpPWpGaD
Cefotetan—ALB—FOXA2 and FOXA3 transcription factor networks—AKT1—prostate cancer	5.73e-05	0.00175	CbGpPWpGaD
Cefotetan—ALB—Metabolism of lipids and lipoproteins—TBXAS1—prostate cancer	5.68e-05	0.00174	CbGpPWpGaD
Cefotetan—ALB—Transmembrane transport of small molecules—SLC22A3—prostate cancer	5.63e-05	0.00172	CbGpPWpGaD
Cefotetan—ALB—Platelet degranulation—VEGFA—prostate cancer	5.56e-05	0.0017	CbGpPWpGaD
Cefotetan—ALB—Vitamin B12 Metabolism—IL6—prostate cancer	5.52e-05	0.00169	CbGpPWpGaD
Cefotetan—ALB—Metabolism of lipids and lipoproteins—ABCG5—prostate cancer	5.47e-05	0.00167	CbGpPWpGaD
Cefotetan—ALB—Hemostasis—GRB7—prostate cancer	5.3e-05	0.00162	CbGpPWpGaD
Cefotetan—ALB—Response to elevated platelet cytosolic Ca2+—VEGFA—prostate cancer	5.3e-05	0.00162	CbGpPWpGaD
Cefotetan—ALB—Metabolism of lipids and lipoproteins—HSD3B2—prostate cancer	5.28e-05	0.00162	CbGpPWpGaD
Cefotetan—ALB—Platelet activation, signaling and aggregation—ITGB3—prostate cancer	5.27e-05	0.00161	CbGpPWpGaD
Cefotetan—ALB—Transmembrane transport of small molecules—ABCG5—prostate cancer	5.2e-05	0.00159	CbGpPWpGaD
Cefotetan—ALB—Metabolism—TST—prostate cancer	5.18e-05	0.00159	CbGpPWpGaD
Cefotetan—ALB—Metabolism—CSAD—prostate cancer	5.18e-05	0.00159	CbGpPWpGaD
Cefotetan—ALB—Metabolism—GRHL1—prostate cancer	5.18e-05	0.00159	CbGpPWpGaD
Cefotetan—ALB—Metabolism—PSAT1—prostate cancer	5.18e-05	0.00159	CbGpPWpGaD
Cefotetan—ALB—Metabolism—ADI1—prostate cancer	5.18e-05	0.00159	CbGpPWpGaD
Cefotetan—ALB—Metabolism—CBR1—prostate cancer	5.18e-05	0.00159	CbGpPWpGaD
Cefotetan—ALB—Platelet degranulation—TGFB1—prostate cancer	5.11e-05	0.00156	CbGpPWpGaD
Cefotetan—ALB—Metabolism of lipids and lipoproteins—LRP2—prostate cancer	5.06e-05	0.00155	CbGpPWpGaD
Cefotetan—ALB—Hemostasis—GNG5—prostate cancer	5.05e-05	0.00154	CbGpPWpGaD
Cefotetan—ALB—Metabolism of lipids and lipoproteins—P4HB—prostate cancer	4.96e-05	0.00152	CbGpPWpGaD
Cefotetan—ALB—Folate Metabolism—TP53—prostate cancer	4.9e-05	0.0015	CbGpPWpGaD
Cefotetan—ALB—Response to elevated platelet cytosolic Ca2+—TGFB1—prostate cancer	4.86e-05	0.00149	CbGpPWpGaD
Cefotetan—ALB—Metabolism—GRHPR—prostate cancer	4.81e-05	0.00147	CbGpPWpGaD
Cefotetan—ALB—Metabolism—UGT2B17—prostate cancer	4.81e-05	0.00147	CbGpPWpGaD
Cefotetan—ALB—Metabolism—CKMT2—prostate cancer	4.81e-05	0.00147	CbGpPWpGaD
Cefotetan—ALB—Metabolism—UGT2B15—prostate cancer	4.81e-05	0.00147	CbGpPWpGaD
Cefotetan—ALB—Metabolism of lipids and lipoproteins—SULT2A1—prostate cancer	4.71e-05	0.00144	CbGpPWpGaD
Cefotetan—ALB—Metabolism of lipids and lipoproteins—MED12—prostate cancer	4.63e-05	0.00142	CbGpPWpGaD
Cefotetan—ALB—Transmembrane transport of small molecules—SLC22A1—prostate cancer	4.59e-05	0.00141	CbGpPWpGaD
Cefotetan—ALB—Metabolism—MBTPS1—prostate cancer	4.53e-05	0.00139	CbGpPWpGaD
Cefotetan—ALB—Metabolism—NAGLU—prostate cancer	4.53e-05	0.00139	CbGpPWpGaD
Cefotetan—ALB—Metabolism—SULT2B1—prostate cancer	4.53e-05	0.00139	CbGpPWpGaD
Cefotetan—ALB—Metabolism—PGAM2—prostate cancer	4.53e-05	0.00139	CbGpPWpGaD
Cefotetan—ALB—Metabolism—RFK—prostate cancer	4.53e-05	0.00139	CbGpPWpGaD
Cefotetan—ALB—Metabolism—GSTM3—prostate cancer	4.53e-05	0.00139	CbGpPWpGaD
Cefotetan—ALB—Metabolism—AOX1—prostate cancer	4.53e-05	0.00139	CbGpPWpGaD
Cefotetan—ALB—Folate Metabolism—IL6—prostate cancer	4.49e-05	0.00137	CbGpPWpGaD
Cefotetan—ALB—Metabolism of lipids and lipoproteins—NCOA3—prostate cancer	4.42e-05	0.00135	CbGpPWpGaD
Cefotetan—ALB—Transmembrane transport of small molecules—GNG5—prostate cancer	4.37e-05	0.00134	CbGpPWpGaD
Cefotetan—ALB—Hemostasis—PRKACB—prostate cancer	4.3e-05	0.00132	CbGpPWpGaD
Cefotetan—ALB—Metabolism—CYP3A43—prostate cancer	4.29e-05	0.00131	CbGpPWpGaD
Cefotetan—ALB—Metabolism—AMACR—prostate cancer	4.29e-05	0.00131	CbGpPWpGaD
Cefotetan—ALB—Metabolism—DEGS1—prostate cancer	4.29e-05	0.00131	CbGpPWpGaD
Cefotetan—ALB—Metabolism—NAT1—prostate cancer	4.29e-05	0.00131	CbGpPWpGaD
Cefotetan—ALB—Metabolism—SRD5A2—prostate cancer	4.29e-05	0.00131	CbGpPWpGaD
Cefotetan—ALB—Metabolism of lipids and lipoproteins—HPGDS—prostate cancer	4.22e-05	0.00129	CbGpPWpGaD
Cefotetan—ALB—Metabolism of lipids and lipoproteins—CYP2C19—prostate cancer	4.19e-05	0.00128	CbGpPWpGaD
Cefotetan—ALB—Hemostasis—THBS1—prostate cancer	4.19e-05	0.00128	CbGpPWpGaD
Cefotetan—ALB—Platelet activation, signaling and aggregation—PIK3CG—prostate cancer	4.13e-05	0.00126	CbGpPWpGaD
Cefotetan—ALB—Metabolism—HSD17B1—prostate cancer	4.09e-05	0.00125	CbGpPWpGaD
Cefotetan—ALB—Metabolism of lipids and lipoproteins—ACHE—prostate cancer	4.09e-05	0.00125	CbGpPWpGaD
Cefotetan—ALB—Platelet activation, signaling and aggregation—EGF—prostate cancer	4.08e-05	0.00125	CbGpPWpGaD
Cefotetan—ALB—Hemostasis—PRKCZ—prostate cancer	4.06e-05	0.00124	CbGpPWpGaD
Cefotetan—ALB—Metabolism of lipids and lipoproteins—AKR1C3—prostate cancer	3.94e-05	0.0012	CbGpPWpGaD
Cefotetan—ALB—Metabolism of lipids and lipoproteins—PRKACB—prostate cancer	3.92e-05	0.0012	CbGpPWpGaD
Cefotetan—ALB—Metabolism of lipids and lipoproteins—CYP17A1—prostate cancer	3.88e-05	0.00119	CbGpPWpGaD
Cefotetan—ALB—Platelet activation, signaling and aggregation—IGF1—prostate cancer	3.78e-05	0.00116	CbGpPWpGaD
Cefotetan—ALB—Transmembrane transport of small molecules—PRKACB—prostate cancer	3.72e-05	0.00114	CbGpPWpGaD
Cefotetan—ALB—Metabolism of lipids and lipoproteins—NCOA2—prostate cancer	3.69e-05	0.00113	CbGpPWpGaD
Cefotetan—ALB—Metabolism—B4GALT4—prostate cancer	3.65e-05	0.00112	CbGpPWpGaD
Cefotetan—ALB—Metabolism—HPGD—prostate cancer	3.65e-05	0.00112	CbGpPWpGaD
Cefotetan—ALB—Platelet activation, signaling and aggregation—PIK3CD—prostate cancer	3.63e-05	0.00111	CbGpPWpGaD
Cefotetan—ALB—Platelet activation, signaling and aggregation—SERPINE1—prostate cancer	3.59e-05	0.0011	CbGpPWpGaD
Cefotetan—ALB—Selenium Micronutrient Network—IL6—prostate cancer	3.57e-05	0.00109	CbGpPWpGaD
Cefotetan—ALB—Transmembrane transport of small molecules—NCOA2—prostate cancer	3.51e-05	0.00107	CbGpPWpGaD
Cefotetan—ALB—Hemostasis—PRKCQ—prostate cancer	3.45e-05	0.00106	CbGpPWpGaD
Cefotetan—ALB—Metabolism—TNFRSF21—prostate cancer	3.43e-05	0.00105	CbGpPWpGaD
Cefotetan—ALB—Hemostasis—PLAUR—prostate cancer	3.41e-05	0.00104	CbGpPWpGaD
Cefotetan—ALB—Transmembrane transport of small molecules—SLC5A5—prostate cancer	3.35e-05	0.00103	CbGpPWpGaD
Cefotetan—ALB—Metabolism—CYP7B1—prostate cancer	3.34e-05	0.00102	CbGpPWpGaD
Cefotetan—ALB—Metabolism—MTAP—prostate cancer	3.34e-05	0.00102	CbGpPWpGaD
Cefotetan—ALB—Platelet activation, signaling and aggregation—JAK2—prostate cancer	3.33e-05	0.00102	CbGpPWpGaD
Cefotetan—ALB—Metabolism of lipids and lipoproteins—CYP1B1—prostate cancer	3.26e-05	0.000998	CbGpPWpGaD
Cefotetan—ALB—Metabolism—SULT1E1—prostate cancer	3.25e-05	0.000995	CbGpPWpGaD
Cefotetan—ALB—Metabolism—SRD5A1—prostate cancer	3.25e-05	0.000995	CbGpPWpGaD
Cefotetan—ALB—Hemostasis—VAV3—prostate cancer	3.16e-05	0.000968	CbGpPWpGaD
Cefotetan—ALB—Platelet activation, signaling and aggregation—PIK3CB—prostate cancer	3.16e-05	0.000968	CbGpPWpGaD
Cefotetan—ALB—Metabolism of lipids and lipoproteins—GGT1—prostate cancer	3.16e-05	0.000967	CbGpPWpGaD
Cefotetan—ALB—Metabolism of lipids and lipoproteins—NCOA1—prostate cancer	3.11e-05	0.000952	CbGpPWpGaD
Cefotetan—ALB—Metabolism—ACSL4—prostate cancer	3.1e-05	0.00095	CbGpPWpGaD
Cefotetan—ALB—Metabolism—HSD17B3—prostate cancer	3.1e-05	0.00095	CbGpPWpGaD
Cefotetan—ALB—Hemostasis—ITPR1—prostate cancer	3.07e-05	0.000939	CbGpPWpGaD
Cefotetan—ALB—Metabolism of lipids and lipoproteins—CYP19A1—prostate cancer	3.07e-05	0.000939	CbGpPWpGaD
Cefotetan—ALB—Metabolism—PHGDH—prostate cancer	2.97e-05	0.00091	CbGpPWpGaD
Cefotetan—ALB—Metabolism—ARG2—prostate cancer	2.97e-05	0.00091	CbGpPWpGaD
Cefotetan—ALB—Metabolism—UMPS—prostate cancer	2.97e-05	0.00091	CbGpPWpGaD
Cefotetan—ALB—Metabolism of lipids and lipoproteins—RXRA—prostate cancer	2.96e-05	0.000906	CbGpPWpGaD
Cefotetan—ALB—Transmembrane transport of small molecules—NCOA1—prostate cancer	2.96e-05	0.000906	CbGpPWpGaD
Cefotetan—ALB—Metabolism—LDHB—prostate cancer	2.92e-05	0.000893	CbGpPWpGaD
Cefotetan—ALB—Platelet activation, signaling and aggregation—IL2—prostate cancer	2.9e-05	0.000889	CbGpPWpGaD
Cefotetan—ALB—Metabolism—CYP3A5—prostate cancer	2.86e-05	0.000876	CbGpPWpGaD
Cefotetan—ALB—Transmembrane transport of small molecules—RXRA—prostate cancer	2.81e-05	0.000861	CbGpPWpGaD
Cefotetan—ALB—Metabolism—PDHA1—prostate cancer	2.77e-05	0.000846	CbGpPWpGaD
Cefotetan—ALB—Metabolism—GSTA3—prostate cancer	2.77e-05	0.000846	CbGpPWpGaD
Cefotetan—ALB—Metabolism—UCP3—prostate cancer	2.77e-05	0.000846	CbGpPWpGaD
Cefotetan—ALB—Metabolism—TCN2—prostate cancer	2.77e-05	0.000846	CbGpPWpGaD
Cefotetan—ALB—Hemostasis—ITGB3—prostate cancer	2.72e-05	0.000831	CbGpPWpGaD
Cefotetan—ALB—Metabolism—HSD3B1—prostate cancer	2.64e-05	0.000807	CbGpPWpGaD
Cefotetan—ALB—Metabolism—SLC22A3—prostate cancer	2.64e-05	0.000807	CbGpPWpGaD
Cefotetan—ALB—Metabolism of lipids and lipoproteins—LPL—prostate cancer	2.56e-05	0.000783	CbGpPWpGaD
Cefotetan—ALB—Platelet activation, signaling and aggregation—SRC—prostate cancer	2.53e-05	0.000775	CbGpPWpGaD
Cefotetan—ALB—Metabolism—TBXAS1—prostate cancer	2.53e-05	0.000774	CbGpPWpGaD
Cefotetan—ALB—Metabolism—GSTA4—prostate cancer	2.53e-05	0.000774	CbGpPWpGaD
Cefotetan—ALB—Metabolism of lipids and lipoproteins—CYP1A1—prostate cancer	2.47e-05	0.000757	CbGpPWpGaD
Cefotetan—ALB—Platelet activation, signaling and aggregation—VEGFA—prostate cancer	2.47e-05	0.000755	CbGpPWpGaD
Cefotetan—ALB—Metabolism—GSTA2—prostate cancer	2.46e-05	0.000754	CbGpPWpGaD
Cefotetan—ALB—Metabolism—SULT1A1—prostate cancer	2.43e-05	0.000745	CbGpPWpGaD
Cefotetan—ALB—Metabolism—ABCG5—prostate cancer	2.43e-05	0.000745	CbGpPWpGaD
Cefotetan—ALB—Hemostasis—PLAU—prostate cancer	2.39e-05	0.000732	CbGpPWpGaD
Cefotetan—ALB—Metabolism—GSTA1—prostate cancer	2.38e-05	0.000728	CbGpPWpGaD
Cefotetan—ALB—Metabolism—NAT2—prostate cancer	2.35e-05	0.00072	CbGpPWpGaD
Cefotetan—ALB—Metabolism—GSTO1—prostate cancer	2.35e-05	0.00072	CbGpPWpGaD
Cefotetan—ALB—Metabolism—HSD3B2—prostate cancer	2.35e-05	0.00072	CbGpPWpGaD
Cefotetan—ALB—Hemostasis—CAV1—prostate cancer	2.33e-05	0.000715	CbGpPWpGaD
Cefotetan—ALB—Platelet activation, signaling and aggregation—TGFB1—prostate cancer	2.26e-05	0.000693	CbGpPWpGaD
Cefotetan—ALB—Metabolism of lipids and lipoproteins—PPARA—prostate cancer	2.26e-05	0.000692	CbGpPWpGaD
Cefotetan—ALB—Metabolism—CYP2C18—prostate cancer	2.25e-05	0.00069	CbGpPWpGaD
Cefotetan—ALB—Metabolism—PLCB2—prostate cancer	2.25e-05	0.00069	CbGpPWpGaD
Cefotetan—ALB—Metabolism—LRP2—prostate cancer	2.25e-05	0.00069	CbGpPWpGaD
Cefotetan—ALB—Metabolism—P4HB—prostate cancer	2.21e-05	0.000677	CbGpPWpGaD
Cefotetan—ALB—Metabolism—SLC22A1—prostate cancer	2.15e-05	0.000658	CbGpPWpGaD
Cefotetan—ALB—Transmembrane transport of small molecules—PPARA—prostate cancer	2.15e-05	0.000658	CbGpPWpGaD
Cefotetan—ALB—Hemostasis—PIK3CG—prostate cancer	2.13e-05	0.000651	CbGpPWpGaD
Cefotetan—ALB—Metabolism of lipids and lipoproteins—CAV1—prostate cancer	2.13e-05	0.000651	CbGpPWpGaD
Cefotetan—ALB—Hemostasis—EGF—prostate cancer	2.1e-05	0.000643	CbGpPWpGaD
Cefotetan—ALB—Metabolism—SULT2A1—prostate cancer	2.1e-05	0.000641	CbGpPWpGaD
Cefotetan—ALB—Metabolism—MED12—prostate cancer	2.06e-05	0.000631	CbGpPWpGaD
Cefotetan—ALB—Metabolism—GNG5—prostate cancer	2.05e-05	0.000626	CbGpPWpGaD
Cefotetan—ALB—Hemostasis—CREBBP—prostate cancer	1.97e-05	0.000604	CbGpPWpGaD
Cefotetan—ALB—Metabolism—NCOA3—prostate cancer	1.97e-05	0.000603	CbGpPWpGaD
Cefotetan—ALB—Hemostasis—IGF1—prostate cancer	1.95e-05	0.000596	CbGpPWpGaD
Cefotetan—ALB—Metabolism of lipids and lipoproteins—PIK3CG—prostate cancer	1.94e-05	0.000593	CbGpPWpGaD
Cefotetan—ALB—Platelet activation, signaling and aggregation—PIK3CA—prostate cancer	1.93e-05	0.00059	CbGpPWpGaD
Cefotetan—ALB—Metabolism—HPGDS—prostate cancer	1.88e-05	0.000575	CbGpPWpGaD
Cefotetan—ALB—Hemostasis—PIK3CD—prostate cancer	1.87e-05	0.000572	CbGpPWpGaD
Cefotetan—ALB—Metabolism—CYP2C19—prostate cancer	1.87e-05	0.000572	CbGpPWpGaD
Cefotetan—ALB—Hemostasis—SERPINE1—prostate cancer	1.85e-05	0.000566	CbGpPWpGaD
Cefotetan—ALB—Metabolism—GSTT1—prostate cancer	1.82e-05	0.000558	CbGpPWpGaD
Cefotetan—ALB—Metabolism—ACHE—prostate cancer	1.82e-05	0.000558	CbGpPWpGaD
Cefotetan—ALB—Metabolism—CYP2A6—prostate cancer	1.8e-05	0.000552	CbGpPWpGaD
Cefotetan—ALB—Metabolism of lipids and lipoproteins—CREBBP—prostate cancer	1.8e-05	0.000549	CbGpPWpGaD
Cefotetan—ALB—Hemostasis—NOS3—prostate cancer	1.77e-05	0.00054	CbGpPWpGaD
Cefotetan—ALB—Metabolism—AKR1C3—prostate cancer	1.75e-05	0.000537	CbGpPWpGaD
Cefotetan—ALB—Metabolism—PRKACB—prostate cancer	1.74e-05	0.000534	CbGpPWpGaD
Cefotetan—ALB—Metabolism—CYP17A1—prostate cancer	1.73e-05	0.000528	CbGpPWpGaD
Cefotetan—ALB—Hemostasis—JAK2—prostate cancer	1.72e-05	0.000525	CbGpPWpGaD
Cefotetan—ALB—Transmembrane transport of small molecules—CREBBP—prostate cancer	1.71e-05	0.000522	CbGpPWpGaD
Cefotetan—ALB—Metabolism of lipids and lipoproteins—PIK3CD—prostate cancer	1.7e-05	0.000521	CbGpPWpGaD
Cefotetan—ALB—Metabolism—NCOA2—prostate cancer	1.64e-05	0.000503	CbGpPWpGaD
Cefotetan—ALB—Hemostasis—PIK3CB—prostate cancer	1.63e-05	0.000499	CbGpPWpGaD
Cefotetan—ALB—Platelet activation, signaling and aggregation—AKT1—prostate cancer	1.57e-05	0.000482	CbGpPWpGaD
Cefotetan—ALB—Metabolism—SLC5A5—prostate cancer	1.57e-05	0.00048	CbGpPWpGaD
Cefotetan—ALB—Metabolism—CYP2E1—prostate cancer	1.53e-05	0.000469	CbGpPWpGaD
Cefotetan—ALB—Metabolism—NQO1—prostate cancer	1.52e-05	0.000464	CbGpPWpGaD
Cefotetan—ALB—Hemostasis—IL2—prostate cancer	1.5e-05	0.000458	CbGpPWpGaD
Cefotetan—ALB—Metabolism—TH—prostate cancer	1.49e-05	0.000457	CbGpPWpGaD
Cefotetan—ALB—Metabolism of lipids and lipoproteins—PIK3CB—prostate cancer	1.48e-05	0.000454	CbGpPWpGaD
Cefotetan—ALB—Metabolism—CYP3A4—prostate cancer	1.48e-05	0.000452	CbGpPWpGaD
Cefotetan—ALB—Metabolism of lipids and lipoproteins—PTGS2—prostate cancer	1.47e-05	0.00045	CbGpPWpGaD
Cefotetan—ALB—Metabolism—CYP1B1—prostate cancer	1.45e-05	0.000445	CbGpPWpGaD
Cefotetan—ALB—Metabolism—GGT1—prostate cancer	1.41e-05	0.000431	CbGpPWpGaD
Cefotetan—ALB—Metabolism—NCOA1—prostate cancer	1.39e-05	0.000424	CbGpPWpGaD
Cefotetan—ALB—Metabolism—CYP19A1—prostate cancer	1.37e-05	0.000418	CbGpPWpGaD
Cefotetan—ALB—Hemostasis—EP300—prostate cancer	1.34e-05	0.000411	CbGpPWpGaD
Cefotetan—ALB—Metabolism—RXRA—prostate cancer	1.32e-05	0.000403	CbGpPWpGaD
Cefotetan—ALB—Hemostasis—SRC—prostate cancer	1.31e-05	0.0004	CbGpPWpGaD
Cefotetan—ALB—Metabolism of lipids and lipoproteins—PTEN—prostate cancer	1.28e-05	0.000392	CbGpPWpGaD
Cefotetan—ALB—Hemostasis—VEGFA—prostate cancer	1.27e-05	0.000389	CbGpPWpGaD
Cefotetan—ALB—Metabolism—COMT—prostate cancer	1.27e-05	0.000389	CbGpPWpGaD
Cefotetan—ALB—Metabolism—GSTP1—prostate cancer	1.26e-05	0.000387	CbGpPWpGaD
Cefotetan—ALB—Metabolism—ITPR1—prostate cancer	1.24e-05	0.000381	CbGpPWpGaD
Cefotetan—ALB—Metabolism of lipids and lipoproteins—EP300—prostate cancer	1.22e-05	0.000374	CbGpPWpGaD
Cefotetan—ALB—Metabolism—TYMS—prostate cancer	1.17e-05	0.00036	CbGpPWpGaD
Cefotetan—ALB—Hemostasis—TGFB1—prostate cancer	1.17e-05	0.000357	CbGpPWpGaD
Cefotetan—ALB—Metabolism—GSTM1—prostate cancer	1.16e-05	0.000355	CbGpPWpGaD
Cefotetan—ALB—Metabolism—LPL—prostate cancer	1.14e-05	0.000349	CbGpPWpGaD
Cefotetan—ALB—Metabolism—CYP1A1—prostate cancer	1.1e-05	0.000337	CbGpPWpGaD
Cefotetan—ALB—Metabolism—ERCC2—prostate cancer	1.09e-05	0.000334	CbGpPWpGaD
Cefotetan—ALB—Hemostasis—KRAS—prostate cancer	1.08e-05	0.000331	CbGpPWpGaD
Cefotetan—ALB—Metabolism—MTHFR—prostate cancer	1.03e-05	0.000314	CbGpPWpGaD
Cefotetan—ALB—Metabolism—PPARA—prostate cancer	1.01e-05	0.000308	CbGpPWpGaD
Cefotetan—ALB—Hemostasis—PIK3CA—prostate cancer	9.93e-06	0.000304	CbGpPWpGaD
Cefotetan—ALB—Hemostasis—TP53—prostate cancer	9.61e-06	0.000294	CbGpPWpGaD
Cefotetan—ALB—Metabolism—CAV1—prostate cancer	9.47e-06	0.00029	CbGpPWpGaD
Cefotetan—ALB—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	9.04e-06	0.000277	CbGpPWpGaD
Cefotetan—ALB—Metabolism—PIK3CG—prostate cancer	8.62e-06	0.000264	CbGpPWpGaD
Cefotetan—ALB—Metabolism—INS—prostate cancer	8.16e-06	0.00025	CbGpPWpGaD
Cefotetan—ALB—Hemostasis—AKT1—prostate cancer	8.12e-06	0.000248	CbGpPWpGaD
Cefotetan—ALB—Metabolism—CREBBP—prostate cancer	7.99e-06	0.000245	CbGpPWpGaD
Cefotetan—ALB—Metabolism—PIK3CD—prostate cancer	7.58e-06	0.000232	CbGpPWpGaD
Cefotetan—ALB—Metabolism—NOS3—prostate cancer	7.16e-06	0.000219	CbGpPWpGaD
Cefotetan—ALB—Metabolism—PIK3CB—prostate cancer	6.61e-06	0.000202	CbGpPWpGaD
Cefotetan—ALB—Metabolism—PTGS2—prostate cancer	6.55e-06	0.0002	CbGpPWpGaD
Cefotetan—ALB—Metabolism—PTEN—prostate cancer	5.71e-06	0.000175	CbGpPWpGaD
Cefotetan—ALB—Metabolism—EP300—prostate cancer	5.45e-06	0.000167	CbGpPWpGaD
Cefotetan—ALB—Metabolism—PIK3CA—prostate cancer	4.03e-06	0.000123	CbGpPWpGaD
Cefotetan—ALB—Metabolism—AKT1—prostate cancer	3.29e-06	0.000101	CbGpPWpGaD
